Esperion Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ESPR Nasdaq 2836 www.esperion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Esperion Therapeutics, Inc.

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Jun 5th, 2025 9:30 am
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - Jun 2nd, 2025 6:00 am
Esperion to Participate in Upcoming June Investor Conferences - May 20th, 2025 6:00 am
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - May 12th, 2025 6:00 am
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines - May 9th, 2025 7:55 am
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference - May 9th, 2025 6:00 am
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 8th, 2025 2:30 pm
HLS Therapeutics Announces Q1 2025 Financial Results - May 8th, 2025 4:32 am
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada - May 8th, 2025 4:30 am
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada - May 8th, 2025 4:30 am
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - May 7th, 2025 10:09 am
Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - May 7th, 2025 1:05 am
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates - May 6th, 2025 5:15 am
Esperion Therapeutics: Q1 Earnings Snapshot - May 6th, 2025 4:10 am
Esperion Reports First Quarter 2025 Financial Results - May 6th, 2025 4:00 am
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? - May 1st, 2025 8:01 am
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for - Apr 29th, 2025 8:01 am
Esperion to Participate in The Citizens Life Sciences Conference - Apr 25th, 2025 6:00 am
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Apr 24th, 2025 6:56 am
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 - Apr 24th, 2025 6:00 am